anti-CD33/anti-CD3 humanized bispecific antibody (Y-mAbs Therapeutics)

N/A

Report date: 2026/03/19 16:53:39

Base Information

Drug Nameanti-CD33/anti-CD3 humanized bispecific antibody (Y-mAbs Therapeutics)
Drug Alias Nameanti-CD3/anti-CD33 bispecific T-cell engager (Y-mAbs Therapeutics)huCD33-BsAb
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsT cell surface glycoprotein CD3 modulators
TargetsMyeloid cell surface antigen CD33T cell surface glycoprotein CD3
Therapy Area/IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesY-Mabs Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesY-Mabs Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A